Intended for healthcare professionals

What is new in methotrexate for psoriasis?

Psoriasis is a chronic, immune-mediated inflammatory skin disease that affects approximately 2–3% of the world’s population. For many patients, it is a lifelong condition; 20–30% of patients will have severe psoriasis and will often require systemic therapy to achieve disease control. Methotrexate was first introduced as a treatment for psoriasis over 50 years ago and, in spite of the development of many new biological treatments, it remains the gold standard systemic therapy for psoriasis in Europe.
Dermatology in practice 2009; 17(2): 4–7
To continue reading this article, please sign in or register.